Synchron is a bioelectronics medicine company that develops neuromodulation solutions for previously-untreatable nervous system conditions.
Synchron has raised $200.0M in total funding. The most recent round was Series D. The last funding was announced in November 2025.
Synchron's investors include Khosla Ventures, Alumni Ventures, ARCH Venture Partners, K5 Global, University of Melbourne.
Synchron is headquartered in Brooklyn, United States.
Synchron is a bioelectronics medicine company that develops neuromodulation solutions for previously-untreatable nervous system conditions.
Synchron is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Synchron — Funding & Investors." VCBacked, November 6, 2025, https://www.vcbacked.co/company/synchron. Accessed September 2, 2026.
VCBacked. (2025). Synchron — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/synchron
{{cite web |title=Synchron — Funding & Investors |url=https://www.vcbacked.co/company/synchron |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated